Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include promising RNA therapies for obesity, liver disease, and genetic disorders, attracting interest from major pharma companies like GSK, Eli Lilly, Novo Nordisk, and Amgen. Upcoming FDA meetings and clinical trial results could act as catalysts for the stock, while acquisition or alternative financing remain possible paths forward.
GSK's hepatitis B treatment, Hibsago (bepirovirsen), received FDA approval for adults with chronic hepatitis B without cirrhosis, supporting Jefferies' forecast of peak annual sales at £2.2 billion. The drug offers a potential functional cure, allowi...
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor respon...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
